3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Gastrointestinal
1
Conditions
Melanoma
4
Advanced Cancer
3
Uveal Melanoma
2
Recurrence
2
Lymphoma, Non-Hodgkin
2
Various Advanced Cancer
1
Squamous Cell Carcinoma of Head and Neck
1
Spinocerebellar Degenerations
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Neoplasm Metastasis
1
Microsatellite Unstable Colorectal Cancer
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Liver Neoplasms
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Glioma
1
Glioblastoma
1
Fallopian Tube Neoplasms
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Brain Neoplasms
1
Advanced Gastric Cancer
1
Interventions
relatlimab
1
daratumumab
1
cobimetinib
1
Nivolumab
1
Ipilimumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Microsatellite Unstable Colorectal Cancer
×
relatlimab
×
Clear all
NCT02060188
2025-11-06
CheckMate142
Bristol-Myers Squibb
Phase 2
Completed
385 enrolled
17 charts
2 FDA